Aberrations retained during treatment could be markers for patients who could benefit from a different treatment regimen, including inhibitors of Cyclin D1 activity, such as palbociclib, an inhibitor of both CDK4 and 6, recently approved by FDA for treatment of patients with advanced breast cancer in combination with antihormonal therapies. The gene discussed is CCND1; the disease is breast cancer.